Imagin Medical Now Trading on the Frankfurt and Stuttgart Stock Exchanges

VANCOUVER, BC and BOSTON, MA--(Marketwired - May 10, 2016) -  Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (the "Company") is pleased to announce that its common shares now trade on the Frankfurt & Stuttgart Stock Exchanges under the symbol "DPD2". European investors can now find quotes for the company on www.frankfurtstockexchange.de/

The Frankfurt Stock Exchange (the "Frankfurt Exchange") is the world's 10^th largest stock exchange by market capitalization and the largest of Germany's seven stock exchanges. The Stuttgart Stock Exchange is the second largest in Germany, handling approximately 40% of all securities trades in the country.

By facilitating advanced electronic trading, settlement and information systems, the Frankfurt Exchange is able to meet the growing requirements of cross-border trading. In addition to specialist trading at the Frankfurt Exchange, its fully electronic trading system XETRA is one of the leading electronic trading systems in the world. Over 200 trading participants from 16 European countries, Hong Kong and the United Arab Emirates are connected via XETRA servers in Frankfurt.

"Our listing on the two leading stock exchanges in Germany, Frankfurt & Stuttgart, will help build our exposure in Europe, and we expect the XETRA electronic trading platform, to increase our trading liquidity in all of the major European financial hubs," said Jim Hutchens, Imagin Medical's President & CEO. Mr. Hutchens concluded that, "We are excited to spread the word about our technology with our listing on these two major German stock exchanges and look forward to growing our shareholder base worldwide."

About Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.

ON BEHALF OF THE BOARD:

Jim Hutchens,

President & CEO

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.